Docetaxel and 5-Fluorouracil: Promising Novel Regimen for Advanced Gastric Cancer

Share this content:

the Cancer Therapy Advisor take:

Researchers sought to establish a more complete understanding of a biweekly dose-dense regimen of docetaxel and 5-fluorouracil as first-line treatment for patients with advanced gastric cancer and the effect is has on matters such as efficacy, safety, and quality of life.

The study included 39 patients with a median age of 55 (range 28-80). The primary endpoint of the study was response rate, and secondary endpoints included progression-free survival, overall survival, quality of life, and toxicity.

Patients were given docetaxel 60 mg/m2 and 5-fluorouracil 400 mg/m2 bolus followed by 2,400 mg/m2 46-hour infusion every 2 weeks. All patients adopted prophylactic use of G-CSF. Researchers found that the response rate in patients was 51.3% and median overall survival and progression-free survival were 14.0 and 6.7 months, respectively.

Adverse events were reported at all grade levels, the most common being anemia (87.2%), fatigue (74.4%), neutropenia (66.7%), nail change (48.7%), and liver dysfunction (38.5%). Grade 3/4 toxicities were noted as anemia (28.2%), liver dysfunction (7.7%), and fatigue (7.7%). The researchers also conducted an analysis focused on quality of life and noted improvements in seven scales and drops in 3 scales.

The researchers concluded that a biweekly dose-dense regiment of docetaxel and 5-fluorouracil as first-line treatment for patients with advanced gastric cancer has promising indications as a tolerable and safe treatment option that improves response rates for patients.

Docetaxel and 5-Fluorouracil: Promising Novel Regimen for Advanced Gastric Cancer
Docetaxel and 5-fluorouracil as first-line treatment for patients with advanced gastric cancer.
This study evaluated the efficacy, safety and impact on quality of life (QoL) of a dose-dense biweekly regimen of docetaxel and 5-fluorouracil in first-line treatment of advanced gastric cancer (AGC). This novel regimen is a promising option for AGC, showing high RR, improvement on QoL and acceptable toxicity.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters